Skip to main
CRVO

CervoMed Inc (CRVO) Stock Forecast & Price Target

CervoMed Inc (CRVO) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CervoMed Inc demonstrates a positive outlook due to its promising clinical trial data, particularly from the Phase 2b RewinD-LB study, which highlights significant reductions in clinical progression of dementia with Lewy bodies among participants, especially those without Alzheimer's co-pathology. The substantial median plasma GFAP reduction of approximately 16% and its correlation with clinical improvements in dementia severity reinforce neflamapimod's mechanism of action and potential for disease modification. Furthermore, with a favorable safety profile maintained across 48 weeks of treatment and encouraging biomarker data supporting therapeutic efficacy, CervoMed's strategic positioning in the market for age-related neurologic disorders appears increasingly compelling.

Bears say

CervoMed faces significant risks that contribute to a negative outlook on its stock, primarily related to the potential delays and challenges in initiating and successfully completing the Phase 3 trial for its lead candidate, neflamapimod, in treating dementia with Lewy bodies (DLB). The company also faces uncertainty regarding regulatory approval and market acceptance, which could be hindered by slower-than-expected uptake and the high likelihood of dilution in the medium term. Additionally, despite some favorable early trial results, the underlying risk of irreversible neuronal loss in patients with DLB remains a substantial concern that could impact overall product viability and market confidence.

CervoMed Inc (CRVO) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CervoMed Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CervoMed Inc (CRVO) Forecast

Analysts have given CervoMed Inc (CRVO) a Strong Buy based on their latest research and market trends.

According to 7 analysts, CervoMed Inc (CRVO) has a Strong Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CervoMed Inc (CRVO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.